Champions Oncology (CSBR) Stock Forecast: StockMap's 2-Week Call
CSBR stock forecast: StockMap's model makes no two-week call on Champions Oncology after the Nov 13 close: its evidence is split, 3 reasons for and 12 against. Right in 2 of 3 two-week windows on CSBR since Sep 24; by chance, a call on the same dates was right 51% of the time.
Champions Oncology last closed at $4.71, +1.29% on the session.
Against the IVW growth benchmark the position is +2.20% over the forecast window.
Champions Oncology's market cap is $65.56M as of November 13, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -18 (too close to call).
Where CSBR sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 3 bullish and 12 bearish.
Agreement across those insights is 80%.
27 daily calls for CSBR so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Champions Oncology in the 24th percentile on return on equity, where 100 is best.
Champions Oncology is classified under Health Care / Life Sciences Tools & Services.
StockMap tracks Champions Oncology as the 40th largest of the 42 companies it covers in the Life Sciences Tools & Services industry, part of the Health Care sector.
Across that group the current two-week reads are 25 Neutral, 13 Moderate Outperform, 3 Moderate Underperform and 1 Strong Underperform.
On that composite Champions Oncology ranks 38th of 42 in the group, against a group median of +0.13.